MedPath

The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)

Phase 4
Completed
Conditions
Pregnancy Result Rape
Interventions
Drug: Leuveris
Registration Number
NCT01016210
Lead Sponsor
The Baruch Padeh Medical Center, Poriya
Brief Summary

To explore whether recombinant LH (rLH) supplementation (Leuveris) to recombinant follicle stimulating hormone (rFSH) following GnRH antagonist treatment has an advantage in infertile women with advanced reproductive ageing undergoing IVF-ET.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • female candidate to IVF
  • between 30-45 years old
Exclusion Criteria
  • not included for fertilization

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
60 infertile womenLeuverisCandidates for IVF-ET treatment
Primary Outcome Measures
NameTimeMethod
Pregnancy rateStarting February 2010
Secondary Outcome Measures
NameTimeMethod
Fertilization rateStarting February 2010 till April 2013

Trial Locations

Locations (1)

Poriya hospital

🇮🇱

Tiberias, Israel

© Copyright 2025. All Rights Reserved by MedPath